



GKPTN: The Global Kidney Patient Trial Network

– March 2024

The George Institute
for Global Health

Facts:

- Collectively, kidney and heart diseases are the number one cause of death worldwide.
- Participant recruitment into clinical trials is crucial for improving treatments for kidney and heart problems.
- There are currently no collaborative global initiatives to streamline recruitment and evidence discovery for patients with chronic kidney disease.

Project Cycle:

2020–ongoing

Partners:

*The George Institute, Australia
George Clinical, Australia
George Clinical Netherlands BV
George Clinical, United States
Clinical trial sites around the world including Argentina, Australia, Brazil, Canada, China, Italy, Japan, Spain, and the United States
International Society of Nephrology*

Supporters:

Astra Zeneca

Principal Investigator:

*A/Prof Sradha Kotwal
Prof Hiddo Lambers Heerspink*

Background:

- Kidney disease is recognised as a global health problem due to its increasing prevalence and the high burden it places on individual patients and healthcare systems.
- The number of clinical trials in chronic kidney disease is lacking behind other specialties due to high costs, lack of global clinical trial networks, and higher than average adverse event rates.
- Innovative approaches that facilitate new trials are highly desired to accelerate the discovery of novel treatments for patients with chronic kidney disease.

Aims:

- Endorsed by the International Society of Nephrology, the Global Kidney Patients Trial Network (GKPTN) aims to establish collaborative global infrastructure to facilitate rapid and increased access to trials for patients with kidney disease.
- The GKPTN aims to improve patient outcomes by hosting embedded trials with novel designs to efficiently test multiple agents faster and more efficiently than current approaches.

Methods:

- The GKPTN is an international collaborative initiative to improve patient outcomes by facilitating the conduct of clinical trials and generating evidence about the efficacy and safety of new treatment strategies.
- Network participants consent to be approached about participation in current or future trials, as well as be followed up at least every six months for a minimum of five years.
- GKPTN-hosted trials are able to recruit patients from the platform, be governed in a centralised collaborative manner, and incorporate new trial methodology and pragmatic solutions.

Impact:

- People living with kidney disease will be able to participate in more trials through the GKPTN.
- The platform will improve research efficiency through the use of global collaboration models and efficient clinical trial designs.
- By bringing patients, established sites and trials closer together, the GKPTN aims to strengthen the global kidney disease research community's capacity to facilitate more rapid translation of new interventions from research into practice.

Contact:

To find out more about this project and its principal investigators or The George Institute please contact Tina Wall +61 410 411 983 or twall@georgeinstitute.org.au

The George Institute For Global Health:

We're improving the lives of millions of people worldwide through innovative health research. Working across a broad health landscape, the Institute conducts clinical, population and health system research aimed at changing health practice and policy worldwide.